Evaluation of Effectiveness of the 23-Valent Pneumococcal Capsular Polysaccharide Vaccine for HIV-Infected Patients

Abstract
PERSONS INFECTED with the human immunodeficiency virus (HIV) are at markedly increased risk for invasive infections with Streptococcus pneumoniae. Among adults, HIV-infected persons have an incidence of invasive pneumococcal disease that is 150 to 300 times greater than that of the general population,1,2 and it is estimated that 15% to 20% of HIV-infected children will have pneumococcal bacteremia during their HIV disease.3